Literature DB >> 2496307

Role of host antibody in the chemotherapeutic action of praziquantel against Schistosoma mansoni: identification of target antigens.

P J Brindley1, M Strand, A P Norden, A Sher.   

Abstract

We have demonstrated previously in a mouse model that effective chemotherapy against Schistosoma mansoni with praziquantel (PZQ) is dependent upon an intact host antibody response. In the same study, it was found that worms recovered from PZQ-treated animals display surface-bound antibodies. In order to identify the target antigens of the antibodies involved in the synergy between PZQ and the immune response, monoclonal antibodies (mAbs) and polyclonal antisera recognizing different tegumental components were tested by indirect immunofluorescence (IF) assay for their ability to bind in vitro to the surface of 6-week-old schistosomes perfused from nude (athymic) mice 1 h after PZQ treatment. Nude mice were used as hosts because worms from these animals were found to lack bound anti-schistosome antibodies. Only 5 of the 21 antibodies tested reacted with drug-treated worms. This indicated that the damage caused by PZQ to the schistosome tegument is restricted to specific tegumental components. Of the positive reactions, one group of antibodies gave IF patterns different from, whereas the other group gave IF reactions similar to those seen with worms perfused from immunologically intact mice. Antibodies against a schistosome esterase and alkaline phosphatase produced reaction patterns in the former category. In contrast, two out of three monoclonal antibodies recognizing different epitopes on a 200-kDa glycoprotein abundant in worm tubercles gave IF patterns very similar to those observed on schistosomes from drug-treated, intact mice. The biological significance of these reactions was confirmed by demonstrating that transfer of one of the positive monoclonal antibodies to 6-week-infected, B cell-depleted (mu-suppressed) mice reconstitutes the efficacy of PZQ treatment to normal levels. The above results suggest that the antibodies involved in the mechanism of action of PZQ react with a limited set of antigens. Furthermore, they implicate the 200-kDa tubercle protein as a major target of this response in naturally infected hosts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496307     DOI: 10.1016/0166-6851(89)90001-7

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  15 in total

Review 1.  Schistosomiasis drug therapy and treatment considerations.

Authors:  K C Shekhar
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Quantification of praziquantel-induced damage on the surface of adult Schistosoma mansoni worms: estimation of esterase and alkaline phosphatase activity.

Authors:  P G Fallon; C McNeice; A J Probert; M J Doenhoff
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

3.  In vivo imaging of schistosomes to assess disease burden using positron emission tomography (PET).

Authors:  Nicolas Salem; Jason D Balkman; Jing Wang; David L Wilson; Zhenghong Lee; Christopher L King; James P Basilion
Journal:  PLoS Negl Trop Dis       Date:  2010-09-21

Review 4.  Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges.

Authors:  Rashad Abdul-Ghani; Naguiba Loutfy; Amel el-Sahn; Azza Hassan
Journal:  Parasitol Res       Date:  2009-03-03       Impact factor: 2.289

Review 5.  Computational vaccinology: an important strategy to discover new potential S. mansoni vaccine candidates.

Authors:  Carina S Pinheiro; Vicente P Martins; Natan R G Assis; Bárbara C P Figueiredo; Suellen B Morais; Vasco Azevedo; Sergio C Oliveira
Journal:  J Biomed Biotechnol       Date:  2011-10-15

6.  Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Sophy Ngom-Wegi; Juliet Ndibazza; Trinh Duong; Birgitte J Vennervald; David W Dunne; Eli Katunguka-Rwakishaya; Alison M Elliott
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

7.  Schistosoma tegument proteins in vaccine and diagnosis development: an update.

Authors:  Cristina Toscano Fonseca; Gardênia Braz Figueiredo Carvalho; Clarice Carvalho Alves; Tatiane Teixeira de Melo
Journal:  J Parasitol Res       Date:  2012-10-18

8.  Immunization with tegument nucleotidases associated with a subcurative praziquantel treatment reduces worm burden following Schistosoma mansoni challenge.

Authors:  Henrique K Rofatto; Bogar O Araujo-Montoya; Patrícia A Miyasato; Julio Levano-Garcia; Dunia Rodriguez; Eliana Nakano; Sergio Verjovski-Almeida; Leonardo P Farias; Luciana C C Leite
Journal:  PeerJ       Date:  2013-04-02       Impact factor: 2.984

9.  Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Nicholas O Emojong; Harriet Mpairwe; Frances M Jones; Trinh Duong; David W Dunne; Birgitte J Vennervald; Eli Katunguka-Rwakishaya; Alison M Elliott
Journal:  BMC Infect Dis       Date:  2009-03-18       Impact factor: 3.090

10.  Epidemiology and interactions of Human Immunodeficiency Virus - 1 and Schistosoma mansoni in sub-Saharan Africa.

Authors:  Humphrey D Mazigo; Fred Nuwaha; Shona Wilson; Safari M Kinung'hi; Domenica Morona; Rebecca Waihenya; Jorg Heukelbach; David W Dunne
Journal:  Infect Dis Poverty       Date:  2013-01-24       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.